Journal
ANNUAL REVIEW OF NEUROSCIENCE, VOL 37
Volume 37, Issue -, Pages 79-100Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-neuro-071013-014300
Keywords
Alzheimer's disease; apolipoprotein E; polymorphism; amyloid-beta; tau; pathogenesis; therapy
Categories
Ask authors/readers for more resources
The vast majority of Alzheimer's disease (AD) cases are late onset (LOAD), which is genetically complex with heritability estimates up to 80%. Apolipoprotein E (APOE) has been irrefutably recognized as the major genetic risk factor, with semidominant inheritance, for LOAD. Although the mechanisms that underlie the pathogenic nature of APOE in AD are still not completely understood, emerging data suggest that APOE contributes to AD pathogenesis through both amyloid-beta (A beta)-dependent and A beta-independent pathways. Given the central role for APOE in the modulation of AD pathogenesis, many therapeutic strategies have emerged, including converting APOE conformation, regulating APOE expression, mimicking APOE peptides, blocking the APOE/A beta interaction, modulating APOE lipidation state, and gene therapy. Accumulating evidence also suggests the utility of APOE genotyping in AD diagnosis, risk assessment, prevention, and treatment response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available